| ACE Inhibitor Use - Current |
294 (61%) |
143 (58%) |
0.426 |
| ACE Inhibitor Use - Ever |
444 (92%) |
216 (87%) |
0.046*
|
| Angiotensin Receptor Blocker Use - Current |
117 (36%) |
57 (31%) |
0.286 |
| Angiotensin Receptor Blocker Use - Ever |
174 (53%) |
85 (46%) |
0.119 |
| Aldosterone Antagonist Use - Current |
81 (27%) |
31 (17%) |
0.019*
|
| Aldosterone Antagonist Use - Ever |
130 (43%) |
49 (27%) |
0.001**
|
| Beta Blocker Use - Current |
467 (82%) |
229 (82%) |
1.000 |
| Beta Blocker Use - Ever |
559 (98%) |
274 (98%) |
0.800 |
| Diuretics Use - Current |
362 (74%) |
188 (75%) |
1.000 |
| Diuretics Use - Ever |
445 (92%) |
223 (88%) |
0.187 |
| Anti-Arrhythmic/Class I Use - Current |
44 (16%) |
10 (6%) |
0.002**
|
| Anti-Arrhythmic/Class I Use - Ever |
81 (29%) |
19 (11%) |
<0.0001**
|
| Anti-Arrhythmic/Class II Use - Current |
34 (13%) |
16 (10%) |
0.283 |
| Anti-Arrhythmic/Class II Use - Ever |
56 (22%) |
16 (10%) |
0.001**
|
| Anti-Arrhythmic/Class III Use - Current |
167 (42%) |
36 (18%) |
<0.0001**
|
| Anti-Arrhythmic/Class III Use - Ever |
259 (65%) |
68 (34%) |
<0.0001**
|
